Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. - Wikidata - awgldk - TriplyDB

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

http://www.wikidata.org/entity/Q34755544

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Strategies to achieve conditional gene mutation in mice Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.Phenotype, development, and biological function of myeloid-derived suppressor cells Genetically engineered mouse models in oncology research and cancer medicine RAS oncogenes: weaving a tumorigenic web Quantitative monitoring of mouse lung tumors by magnetic resonance imaging.Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies Combination immunotherapy: a road map.Rapid modelling of cooperating genetic events in cancer through somatic genome editing p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome.Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.Controversies in clinical cancer dormancy Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche Update in lung cancer and oncological disorders 2010 New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model Expression of tumour-specific antigens underlies cancer immunoediting An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance.Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy.Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.Whole-exome sequencing identifies variants in invasive pituitary adenomas.Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.Strategies for optimizing the response of cancer and normal tissues to radiation.Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

P2860

Q21131200-09FE6766-979E-4ECB-922B-51EF8E12BBAC Q26779184-971F31C6-3637-42D6-A3D4-EB935DDA37E1 Q27023444-659BB3B2-97A0-4B89-AFEF-7147C049D368 Q27310763-1D8C9F92-D272-4D4E-BFA2-E7365ED00D94 Q28079046-B5674E96-CA0B-4690-AB36-877E38B25CF4 Q28079323-4439262B-6CBC-47C2-B1F6-6183B9FAE16D Q28250360-C85BCC15-7766-4418-861E-D7B0CE7F5703 Q30560325-160FBF12-F96A-47BB-9C73-9273D507F05E Q33557006-E2D27DF7-633F-49F9-8BF0-27722EDBC2DE Q33588711-FBA61166-AAF1-425A-9651-66D22541F2D6 Q33862822-45126175-998D-4BA6-B2CA-91012B43344E Q34387974-9E0043C3-A23F-42E0-9F2B-EB79DA2FB5E3 Q34511672-18B253B0-F659-4047-857E-7725D49FCC2A Q34552128-BD86855E-6629-4EF8-ABC6-87C41B4300CB Q34938584-BF1A3537-6FD4-425B-891E-FBBCFB498489 Q35103179-AE4BBC76-FEF4-43B1-8EB2-478473FD5F9D Q35121535-5FE7C88B-FBB9-45E8-BDE8-90D5B7A384BD Q35134139-CAF0E9C3-96D0-4185-8C8E-C72D45365C95 Q35201294-14F01344-70AE-4C03-A2B9-831569CEBF37 Q35219727-344F1C08-EC3E-4167-8F28-360F22B90E6F Q35300077-45CABCDF-BF95-408F-A0D5-8B104A0F2C6F Q35641792-0D1A8BBA-B2EF-47BC-AAFB-E957F9BA2E4C Q35785378-9C63CAE0-3306-4CE2-B618-8FF3B0F93AE2 Q35866682-43C5FC14-FD5A-49EE-825B-B1BBA322B5D5 Q35873571-6CE1C579-FC70-4604-A7AD-3E1C3C4B6000 Q36069862-C8AD92B6-D8B0-477F-814E-99D5A4818552 Q36494634-93A8F502-C737-472D-8089-F8755A2C97B1 Q36710986-1EC9E212-4C47-434F-A5C3-8ACCEE682834 Q36811505-280AC61B-6895-4753-A05A-9E38F02ABDAF Q36891038-D4F1319A-4DB0-4D53-AF35-21C95D6B30EB Q36915205-53C7F46D-FFCB-4F21-956F-8F5E2FDFEF7B Q37028031-D944E8DF-5687-4A26-9344-B800F53CD543 Q37040899-A74EC1D6-D5D6-49E2-8B0C-7DC98398350F Q37107843-9D10A699-C1E0-4FD4-899D-9B8561A254C0 Q37261700-FF15EA88-9F9C-45A4-B040-F1BEC15B0C91 Q37288391-78543973-26AB-45DE-912D-1CDCEBC78E7F Q37369422-7F10B95C-7CAD-42E4-B3F2-C2611A2162B8 Q37531724-30B8C0E0-6DD5-4339-ABB3-1034763EB6F3 Q37542092-C41C5F7E-E2C5-4062-92D6-C3073EF0E502 Q37554718-A9B57306-11CD-465A-B917-0DE4E3263C8B

P2860

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

http://www.wikidata.org/entity/Q34755544

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Endogenous T cell responses to ...... y malignant tumor progression.

@ast

Endogenous T cell responses to ...... y malignant tumor progression.

@en

Endogenous T cell responses to ...... y malignant tumor progression.

@nl

type

label

Endogenous T cell responses to ...... y malignant tumor progression.

@ast

Endogenous T cell responses to ...... y malignant tumor progression.

@en

Endogenous T cell responses to ...... y malignant tumor progression.

@nl

prefLabel

Endogenous T cell responses to ...... y malignant tumor progression.

@ast

Endogenous T cell responses to ...... y malignant tumor progression.

@en

Endogenous T cell responses to ...... y malignant tumor progression.

@nl

P1433

Q34755544-1B64A573-63FD-46F6-92EB-CFA562B743AA

P1476

Q34755544-4D3BE08D-8BE7-41FD-A571-120C2E222213

P2093

Q34755544-05083748-1E6B-4071-8287-166F8C84EABE

Q34755544-28E8E650-ECF1-4874-A30A-42260278BA39

Q34755544-5A2EC310-04E9-4FF2-AC8B-546F093B3014

Q34755544-70D19160-A920-49DB-947B-C2BEA5E824C1

Q34755544-9C46CECA-97D8-4315-8DD3-7BEF9B03B90E

Q34755544-A37D099C-D384-423E-A4E1-04703519B7C0

Q34755544-B64E7C84-1D48-4E73-91C5-5D29F95F2BBE

Q34755544-EE1988F3-C522-418A-BFCB-A80E70BDFD9C

Q34755544-F60F6D9C-3C1A-4250-810C-24CCD86107CE

P2860

Q34755544-09C63D5D-637E-4C77-AF49-CFBA069D6B9C

Q34755544-0F4B9345-FA8D-4D0B-899D-0F57AF4AC32D

Q34755544-1A59B26A-5744-43F7-A084-7CF0731151F3

Q34755544-28DA7CB4-9582-4EB2-B4FE-20AD471AF70E

Q34755544-2D997965-D5F6-4873-A56B-115052DE5F4F

Q34755544-3E9EF5FC-B620-4B3D-9F33-DD88CB75A77C

Q34755544-3F110AB5-971B-4A2B-BFE7-0FDD32DFFEDE

Q34755544-51AD9BC2-80DC-4F74-9479-33BFB7CFBA26

Q34755544-52F643B8-9501-4CF3-B93B-44305A2F4402

Q34755544-56734C2F-8154-4394-B6BE-2BCF757311A7

P304

Q34755544-FD2A1E22-8664-4C19-8DA9-99DBBE5F7BE1

P31

Q34755544-66EDF5E1-7DBB-4B80-B12A-693C76CDFB1C

P356

Q34755544-410102D2-3A6D-4C11-AA35-193A4ABAB606

P433

Q34755544-5275069B-7A55-4F39-966E-024C3B866E26

P478

Q34755544-00F46342-FDAA-45C1-97B0-B59E23B2DE58

P577

Q34755544-203AC7AB-47F6-4420-AA6F-10F810FB88C0

P5875

Q34755544-CAC6A8BF-8956-466A-80DF-D33EBFA51761

P698

Q34755544-57645BA4-FB9F-431E-931A-6C337F88ADE8

P921

Q34755544-DBB23952-880D-4797-9486-264D305A1064

P932

Q34755544-0E562187-5BA8-4F33-9A59-4E5A5F4620F0

P356

J.CCR.2010.11.011

P1433

P1476

Endogenous T cell responses to ...... y malignant tumor progression.

@en

P2093

Ann F Cheung

http://www.w3.org/2001/XMLSchema#string

Claire Mazumdar

http://www.w3.org/2001/XMLSchema#string

Denise Crowley

http://www.w3.org/2001/XMLSchema#string

Jianzhu Chen

http://www.w3.org/2001/XMLSchema#string

Leah M Schmidt

http://www.w3.org/2001/XMLSchema#string

Michel DuPage

http://www.w3.org/2001/XMLSchema#string

Monte M Winslow

http://www.w3.org/2001/XMLSchema#string

Roderick Bronson

http://www.w3.org/2001/XMLSchema#string

Tyler Jacks

http://www.w3.org/2001/XMLSchema#string

P2860

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

Somatic mutations affect key pathways in lung adenocarcinoma

The consensus coding sequences of human breast and colorectal cancers

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Cancer immunoediting: from immunosurveillance to tumor escape

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

T-cell quality in memory and protection: implications for vaccine design

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

Stromal gene expression predicts clinical outcome in breast cancer.

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

P304

72-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2010.11.011

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49771237

http://www.w3.org/2001/XMLSchema#string

P698

21251614

http://www.w3.org/2001/XMLSchema#string

P921

P932

3069809

http://www.w3.org/2001/XMLSchema#string